Direct-to-Patient Distribution for Decentralized Clinical Trials: A Practical Guide

What direct-to-patient distribution means for decentralized trials

Direct-to-patient (DTP) distribution delivers investigational products straight to a participant’s home, which is what makes decentralized and hybrid clinical trials possible. Instead of asking every patient to travel to a site, a clinical trial supply partner coordinates compliant, temperature-controlled delivery to the door. For sponsors running studies in rare diseases or across dispersed populations, DTP can be the difference between slow enrollment and a trial that keeps to its timeline.

Clinical Services International (CSI) supports DTP as part of its end-to-end supply services, combining sourcing, storage and distribution so a decentralized study runs from one coordinated supply chain rather than several disconnected vendors.

The four direct-to-patient models

There is no single way to run DTP, so CSI offers four flexible direct-to-patient services and helps sponsors match one to their protocol:

Clinical Site-to-Patient ships the investigational product from the main or sub depot to the patient’s home, with home nurse services added when needed. Depot-to-Patient delivers from a GMP depot directly to the patient and is well suited to temperature-sensitive products. Pharmacy-to-Patient delivers from a central pharmacy to the patient, again with strong temperature control. The Hybrid option sends products from a site depot or central pharmacy to a home nurse, who then hands them to the patient during a home visit.

When direct-to-patient is the right choice

DTP is most valuable when patients are hard to reach or few in number. It is well suited to trials involving a rare disease, an orphan indication, or a geographically dispersed patient population, where every additional site visit risks dropout. If your study struggles with recruitment or retention, a DTP or hybrid model can widen the pool of eligible participants and keep them engaged through to the end.

Benefits: timelines, quality, cost, and retention

Adopted well, DTP can decrease timelines, improve quality, reduce costs, and help enroll and retain more patients. Bringing the trial to the patient reduces the burden of participation, which supports both recruitment and the data quality that comes from keeping participants in the study rather than losing them to travel and scheduling.

Challenges to plan for: complexity and compliance

DTP also adds moving parts. The main challenges are process complexity and ensuring GMP compliance at every handoff between depot, courier, nurse, and patient. Each model has to protect the chain of custody and the product’s condition, which is why careful planning matters as much as the delivery itself.

How a supply partner keeps DTP compliant and cold

Temperature control is central to DTP because many investigational products are biologics or other cold-chain medicines. CSI provides end-to-end cold and ultra-cold chain logistics at 2 to 8C, -20C, and -80C, using GDP-compliant processes, validated packaging, and qualified couriers, with real-time temperature monitoring and data logging, supported by a global depot network across 60 countries and six continents. This sits within CSI’s wider storage and distribution service and is backed by an independent quality and regulatory team that keeps each shipment compliant across regions.

How to get started

A well-designed direct-to-patient strategy can unlock enrollment, protect quality, and keep a decentralized study on schedule. To map a DTP or hybrid model to your trial, contact CSI to discuss your requirements.

Key Takeaways and FAQ

In short, direct-to-patient distribution makes decentralized trials possible by delivering investigational products to participants' homes. Choosing the right DTP model, and planning for compliance and cold chain, keeps a study on schedule. The questions below cover the essentials.

What is direct-to-patient distribution in clinical trials?

Direct-to-patient (DTP) distribution delivers investigational products straight to a participant’s home, which enables decentralized and hybrid trials. It reduces the need for site visits and is especially useful for rare disease, orphan indication, or geographically dispersed studies.

What are the direct-to-patient models?

CSI offers four models: Clinical Site-to-Patient, Depot-to-Patient, Pharmacy-to-Patient, and Hybrid. They differ in where the product ships from and whether a home nurse is involved, and each is designed to protect temperature control and compliance.

How is temperature control maintained in direct-to-patient delivery?

CSI uses end-to-end cold and ultra-cold chain logistics at 2 to 8C, -20C, and -80C, with GDP-compliant processes, validated packaging, qualified couriers, and real-time temperature monitoring and data logging.